Dr. Stelios Papadopoulos, Ph.D., is Independent Director of Biogen Idec Inc., since July 2008. Dr. Papadopoulos is the Chairman of Exelixis, Inc., a drug discovery and development company that he cofounded in 1994. Previously, he was an investment banker with Cowen & Co., LLC, a financial services company, focusing on the biotechnology and pharmaceutical sectors, from 2000 until his retirement as Vice Chairman in August 2006. Prior to joining Cowen & Co., Dr. Papadopoulos served for 13 years as an investment banker at PaineWebber, Inc., a financial services company, where he was most recently Chairman of PaineWebber Development Corporationration, a PaineWebber subsidiary focusing on biotechnology
Age: 68 Director Since 2008 Ph.D
|Papadopoulos is a member of the boards of directors of BG Medicine, Inc. and Regulus Therapeutics, Inc., both life sciences companies. During the past five years, Dr. Papadopoulos has also served as a director of Anadys Pharmaceuticals, Inc., a biopharmaceutical company.|
The company has return on total asset (ROA) of 12.81 % which means that it generated profit of $12.81 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 22.05 % meaning that it created $22.05 on every $100 dollars invested by stockholders.
The company currently holds 915.15 M in liabilities with Debt to Equity (D/E) ratio of 0.12 which may suggest the company is not taking enough advantage from borrowing. Biogen Idec Inc has Current Ratio of 4.08 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Entity SummaryBiogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec Inc [BIIB] is traded on NASDAQ in USA. It is located in Weston, MA and employs 5,950 people. Filter other
|Click to run this filter|| |
Filter Other Insiders
| BIIB Nasdaq
Biogen Idec Inc
Biogen Idec Inc has less than 1.0 (%) percent chance of experiencing financial distress in the next 2 years of operations.
Biogen price boundaries
Promote Biogen and Stelios Papadopoulos